lopinavir has been researched along with Critical Illness in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 12 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amaya Villar, R; Breval Flores, A; Bustelo Bueno, P; Cantón Bulnes, ML; de la Fuente, C; de la Hoz, C; de San José Bermejo Gómez, A; Díaz Torres, I; Díez Del Corral Fernández, B; Estecha, MA; Estella, Á; Fernández Ruiz, L; Garcia Garmendia, JL; Garnacho Montero, J; Gimenez Beltrán, B; Gomez de Oña, J; Gómez González, C; Guerrero Marín, M; Ibañez Cuadros, S; Loza, A; Machado Casas, JF; Matallana Zapata, DF; Mora, J; Moreno Barriga, E; Moreno Cano, SG; Muñoz, N; Ocaña Fernández, D; Ortega Ordiales, A; Pérez Ruiz, M; Recuerda Núñez, M; Rios Toro, JJ; Rivera Espinar, F; Rodriguez Higueras, MI; Rodriguez Mejías, C; Rojas Amezcua, M; Ruiz Cabello Jimenez, MA; Sainz de Baranda Piñero, A; Tejero-Aranguren, J; Yaguez Mateos, L; Yuste, ME; Zaheri Beryanaki, M | 1 |
| Al-Beidh, F; Angus, DC; Annane, D; Arabi, YM; Beane, A; Berry, LR; Berry, S; Bhimani, Z; Bonten, MJM; Bradbury, CA; Brunkhorst, FM; Burrell, A; Buxton, M; Buzgau, A; Charles, WN; Cove, M; Derde, LPG; Detry, MA; Estcourt, LJ; Fagbodun, EO; Fitzgerald, M; Girard, TD; Goligher, EC; Goossens, H; Gordon, AC; Green, C; Haniffa, R; Higgins, AM; Hills, T; Horvat, CM; Huang, DT; Ichihara, N; Lamontagne, F; Lawler, PR; Lewis, RJ; Lorenzi, E; Marshall, JC; McArthur, CJ; McAuley, DF; McGlothlin, A; McGuinness, SP; McQuilten, Z; McVerry, BJ; Mouncey, PR; Murthy, S; Neal, MD; Nichol, AD; Parke, RL; Parker, JC; Parry-Billings, K; Peters, SEC; Reyes, LF; Rowan, KM; Saito, H; Santos, MS; Saunders, CT; Serpa-Neto, A; Seymour, CW; Shankar-Hari, M; Stronach, LM; Turgeon, AF; Turner, AM; van Bentum-Puijk, W; van de Veerdonk, FL; Webb, SA; Zarychanski, R | 1 |
| Chen, X; Chen, Y; Dhuromsingh, M; Fang, F; Huang, Y; Jiao, R; Li, H; Li, Y; Luo, X; Ning, Q; Qiu, L; Sun, Z; Tian, N; Xu, R; Zeng, F; Zhang, A; Zhang, Y | 1 |
| Andini, R; Bertolino, L; Corcione, A; Durante-Mangoni, E; Florio, LL; Mele, F; Murino, P; Zampino, R | 1 |
| Arzoine, J; Beurton, A; Boutolleau, D; Bureau, C; Burrel, S; Clarac, U; Clovet, O; De Sarcus, M; Decavele, M; Delemazure, J; Deleris, R; Demoule, A; Dres, M; Duceau, B; Faure, M; Grisot, PH; Haudebourg, L; Le Marec, J; Lecronier, M; Mayaux, J; Mora, P; Morawiec, E; Nemlaghi, S; Pari, MH; Raux, M; Virolle, S | 1 |
| Luo, S; Tian, M; Wang, L; Xia, W; Zeng, Y; Zha, Y; Zhang, K; Zhang, X | 1 |
| Carboni Bisso, I; Catanzariti, A; Las Heras, M; Vecchio, G; Zapico, V | 1 |
| Demir, G; Dheir, H; Erdem, AF; Güçlü, E; Kocayiğit, H; Özmen Süner, K; Tomak, Y; Yaylacı, S | 1 |
| Emani, SR; Emani, VR; Goswami, S; Nandanoor, D; Reddy, NK; Reddy, R | 1 |
| Daniel, NM; Hilden, P; Raja, K; Smoke, SM | 1 |
| Bartoletti, M; Gaibani, P; Ranieri, VM; Re, MC; Tonetti, T; Viale, P | 1 |
| Angus, DC; Annane, D; Arabi, YM; Beane, A; Beasley, R; Beidh, FA; Berry, LR; Berry, S; Bhimani, Z; Bonten, MJM; Bradbury, CA; Brunkhorst, FM; Buxton, M; Buzgau, A; Cheng, A; De Jong, M; Derde, LPG; Detry, MA; Duffy, EJ; Estcourt, LJ; Fitzgerald, M; Fowler, R; Girard, TD; Goligher, EC; Goossens, H; Gordon, AC; Green, C; Haniffa, R; Higgins, AM; Hills, TE; Horvat, CM; Huang, DT; King, AJ; Lamontagne, F; Lawler, PR; Lewis, R; Linstrum, K; Litton, E; Lorenzi, E; Malakouti, S; Marshall, JC; McArthur, C; McAuley, DF; McGlothlin, A; Mcguinness, S; McVerry, BJ; Montgomery, SK; Morpeth, SC; Mouncey, PR; Murthy, S; Nichol, AD; Orr, K; Parke, R; Parker, JC; Patanwala, AE; Rowan, KM; Santos, MS; Saunders, CT; Seymour, CW; Shankar-Hari, M; Swaidan, LA; Tong, SYC; Turgeon, AF; Turner, AM; Van de Veerdonk, FL; Webb, SA; Zarychanski, R | 1 |
1 review(s) available for lopinavir and Critical Illness
| Article | Year |
|---|---|
Randomised controlled trials for COVID-19: evaluation of optimal randomisation methodologies-need for data validation of the completed trials and to improve ongoing and future randomised trial designs.
Topics: COVID-19; COVID-19 Drug Treatment; Critical Illness; Hospitalization; Humans; Hydroxychloroquine; Lopinavir; Mortality; Randomized Controlled Trials as Topic; Ritonavir; Selection Bias | 2021 |
1 trial(s) available for lopinavir and Critical Illness
| Article | Year |
|---|---|
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial.
Topics: Adult; Antiviral Agents; Bayes Theorem; COVID-19 Drug Treatment; Critical Illness; Drug Combinations; Humans; Hydroxychloroquine; Lopinavir; Ritonavir; SARS-CoV-2 | 2021 |
10 other study(ies) available for lopinavir and Critical Illness
| Article | Year |
|---|---|
Predictive factors of six-week mortality in critically ill patients with SARS-CoV-2: A multicenter prospective study.
Topics: Cohort Studies; COVID-19; Critical Illness; Female; Hospital Mortality; Humans; Infant; Lopinavir; Male; Middle Aged; Prospective Studies; Ritonavir; SARS-CoV-2 | 2022 |
Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial.
Topics: Adrenal Cortex Hormones; Adult; Anticoagulants; Bayes Theorem; COVID-19; COVID-19 Serotherapy; Critical Illness; Female; Follow-Up Studies; Humans; Hydroxychloroquine; Lopinavir; Male; Middle Aged; Receptors, Interleukin-6; Ritonavir; SARS-CoV-2 | 2023 |
A Case of Critically Ill Infant of Coronavirus Disease 2019 With Persistent Reduction of T Lymphocytes.
Topics: Betacoronavirus; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Coronavirus Infections; COVID-19; Critical Illness; Humans; Infant; Lopinavir; Lymphocyte Count; Male; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Virus Shedding | 2020 |
Early experience with remdesivir in SARS-CoV-2 pneumonia.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Chemical and Drug Induced Liver Injury; Convalescence; Coronavirus Infections; COVID-19; Critical Illness; Darunavir; Drug Administration Schedule; Drug Combinations; Fatal Outcome; Humans; Hydroxychloroquine; Lopinavir; Multiple Organ Failure; Pandemics; Pneumonia, Viral; Ritonavir; RNA, Viral; SARS-CoV-2; Torsades de Pointes | 2020 |
Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis.
Topics: Aged; Coronavirus Infections; COVID-19; Critical Illness; Drug Combinations; Female; Humans; Hydroxychloroquine; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Retrospective Studies; Ritonavir; Standard of Care; Treatment Outcome | 2020 |
The combined therapy of a traditional Chinese medicine formula and Western medicine for a critically ill case infected with COVID-19.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Critical Illness; Drug Combinations; Drugs, Chinese Herbal; Female; Humans; Indoles; Lopinavir; Medicine, Chinese Traditional; Methylprednisolone; Middle Aged; Moxifloxacin; Noninvasive Ventilation; Oxygen Inhalation Therapy; Pandemics; Pneumonia, Viral; Qi; Ritonavir; SARS-CoV-2 | 2020 |
[Adverse effects of lopinavir/ritonavir in critically ill patients with COVID-19].
Topics: Adult; Aged; Argentina; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Critical Illness; Cytochrome P-450 CYP3A Inhibitors; Female; Humans; Lopinavir; Male; Pandemics; Pneumonia, Viral; Retrospective Studies; Ritonavir; SARS-CoV-2; Treatment Outcome | 2020 |
Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19.
Topics: Amides; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Critical Illness; Drug Combinations; Female; Humans; Intensive Care Units; Length of Stay; Lopinavir; Male; Middle Aged; Mortality; Pyrazines; Ritonavir; SARS-CoV-2; Treatment Outcome; Turkey | 2021 |
Early clinical outcomes with tocilizumab for severe COVID-19: a two-centre retrospective study.
Topics: Antibodies, Monoclonal, Humanized; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Critical Illness; Female; Humans; Hydroxychloroquine; Lopinavir; Male; Middle Aged; Oxygen; Retrospective Studies; Ritonavir; Time Factors; Treatment Outcome | 2021 |
Antiviral activity of interferon-based combination therapy in critically ill patients with COVID-19: Preliminary observations.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Critical Illness; Drug Therapy, Combination; Humans; Hydroxychloroquine; Interferon beta-1a; Interferons; Lopinavir; Ritonavir; SARS-CoV-2; Viral Load | 2021 |